{"name":"AB Science","slug":"ab-science","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"AB1010","genericName":"AB1010","slug":"ab1010","indication":"Metastatic breast cancer","status":"phase_2"},{"name":"Masitinib (4.5)","genericName":"Masitinib (4.5)","slug":"masitinib-4-5","indication":"Gastrointestinal stromal tumor (GIST)","status":"phase_3"},{"name":"Masitinib (6.0)","genericName":"Masitinib (6.0)","slug":"masitinib-6-0","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"14C-AB1010","genericName":"14C-AB1010","slug":"14c-ab1010","indication":"Other","status":"phase_1"},{"name":"AB8939","genericName":"AB8939","slug":"ab8939","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Riluzole (100 mg)","genericName":"Riluzole (100 mg)","slug":"riluzole-100-mg","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_3"}]}],"pipeline":[{"name":"14C-AB1010","genericName":"14C-AB1010","slug":"14c-ab1010","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB1010","genericName":"AB1010","slug":"ab1010","phase":"phase_2","mechanism":"AB1010 is a small molecule that targets the PI3K pathway.","indications":["Metastatic breast cancer"],"catalyst":""},{"name":"AB8939","genericName":"AB8939","slug":"ab8939","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Masitinib (4.5)","genericName":"Masitinib (4.5)","slug":"masitinib-4-5","phase":"phase_3","mechanism":"Masitinib is a tyrosine kinase inhibitor that selectively targets c-KIT, PDGFR, and Lyn kinases to modulate immune cell function and reduce pathological inflammation.","indications":["Gastrointestinal stromal tumor (GIST)","Amyotrophic lateral sclerosis (ALS)","Pancreatic cancer","Mastocytosis"],"catalyst":""},{"name":"Masitinib (6.0)","genericName":"Masitinib (6.0)","slug":"masitinib-6-0","phase":"phase_3","mechanism":"Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGF receptor, and Lyn kinase to modulate immune cell activation and reduce inflammatory responses.","indications":["Amyotrophic lateral sclerosis (ALS)","Pancreatic cancer","Mastocytosis","Severe asthma"],"catalyst":""},{"name":"Riluzole (100 mg)","genericName":"Riluzole (100 mg)","slug":"riluzole-100-mg","phase":"phase_3","mechanism":"Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons.","indications":["Amyotrophic lateral sclerosis (ALS)","Other neurodegenerative conditions (under investigation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYk14b3NXejlUVDJkbUN0OEhMR0pCSDFDa3pzYVZCYkxHNG9mUmJLSVZ5OUZTeVVKYUpaR3FnWmxvWGlzUWZRVHFpR3NXTHNEa2N6SkcyVGlfb3hLeGp5dFkyQzI2N1dmNXp5ZzRUbWFKWWxqQmNYMUZKUWo1dml3ZUMwQjB3cXJNMzI0ZldLOTFmS0lpb0o1X0RjazMxemg5dDQwZFk1S1lKMzVMRTRCSnN6NkNDa2xIMTNmRUtHNV8tZzh1Q3AySGo1Ym1aTnJoeVh1STVnLTBxYlROSmNHQnc0LVBCUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart.com","summary":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQWTJVTGh0ejN2YjM1TlN0dzlINUI2X0dubnVSWHdzTGxaZFBRM3RqNm14LWdMWERyamxIbW1YTHZLRWhpbDhDR3dFNHIwSWxMWGZOQXBweEpPdG9qakYwNUoySzZZN0lQQlV2a1FDX0Z0ZmxDYlREY0tmSVpYYkR6YjY4OWlseUFTWmF3VG1fMElGeXNTczZsTEFFdFpOTy1JN3ZJMnd5NGFTNXpaeXRINnNkWVBTVW1zbUlwZGNROUZnR0xvcXpLcFh1dXdmMEFMUGJYU2dMNV9Zdm9VcktZMUU4WUQzZmxrcEdqVXRQT1RtbWhlS1NZYTk0WmVqWUdZakhvZGIwaVdMVU84MDAyNkVZOFhlNkRFODR5T2ZzTzQzOWpPMjF0cktlcDVZNl9Nc0hkbWc5ZldWZm1iSlVNaWx3aURiWF9lUnc?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxQbkk4RVM2cUo5VGtyaWdnc3RMSG53bUlMbEtNb2dyZHcwWEd1M3BJaGIzclhvTzFhLUJXQlJlRXpLLS15bWN5MkRWMXE4YzNxX00tZEk5ZGp2ZWtkdUduUHV0eE9wY0p0Sm5DYzZNTHd4QjdWdS1lTU5UMVo3U0tKUEl4eE5DcmhkbXhXbGRMbmxXOFN0aVJXUl9wVlRwdTJfTnMzU1hoT0VBTG4xeFA3WW1UOFJNTEJ1VEpJMmFPNlN6SDBFWXJ0bGQwN0lRaDYxX2tQZl9XOXJ6ZGp4U3Vpby1mUDhmMzFrbVMwU01ycnlWZEh3NkVMSTN6SkEyc2lzRnpKeUVFSDRRc3N1WjV1WWxKOERXSkI1cmxjVmh0VndTWjRuTmNqM095cW1Jc2pVcUFRRkU4TGFjOXN3UlBianctbUxfb1NhMWF5Z1BR?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOaWJHTkVvd3diWm9pX3c0aEx4MnZfMmRmRkczT3g4ZkE1RmE4eU1Qd1JmSXBsVThCYUlib0dLNEt1M0tVOHlZNnBodFpuRngxM2kyOFBkOUlENlB6bUx4Q2NqUmY4ek02SmtlT1h6ZUQ0M29nYzJtVkNUTC01aEpyUkN5VXBSV3U4aDczQ0NqMVFWRjcwTHd4ejdFT3ZLTjNtaWdhT3pKNkYtWlY1REJaUEk0VWN4UjdLaWg5NFhtbkhqUXJCekhoWnB1RG5FTFRpOEttc1RwLVY1VGdQSlB6M2hlcC1KTENhSC01WWRtNXh4NnVCNDN3YkJTZURpOTg?oc=5","date":"2026-01-20","type":"pipeline","source":"PR Newswire","summary":"PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight - PR Newswire","headline":"PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxPcG02MzkwN3FNRFZGZnFTVEZWUXpIaUtiYVBNMlFkVEVOLS1OTVhhcWVUM284VkR1T0FNQkNWM2hxWE9HUXlmX1ZUTTBsRWZpOFlGVVExT19vMy0tX2hPRXRaX3FoMEQ5MFR5MEx2TVBIYV9DeUw1Q21FVzBYcWpNdXFMRkZtTWxuNjl3ZlE4VEZhYklIV295alFMeml3RzF4WlEzX0RkdHNTdkV3eG9sUGFUYjVtenlIR1VnV1RCQ293blNONVhnUGRBY3c4bFpsdW5WZzFWeEdoM0QxN2gwZmxnTmRkanBmU2VZNE43cVRveDlWVW5hekNnV3NvZWpjbnlxYjFYRVh4dkpWLVFHeU9sNEZkdVJ5eUZWRWF6TFhqV3N4a054V3VnZEY1aGx2UmFwVEpkZEZoVy1QNklnWVo2X2hCc2lydjhYVHotS0VyT3I0ZVgwcnRkaUg0dGxZ?oc=5","date":"2026-01-05","type":"regulatory","source":"PR Newswire UK","summary":"Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment | DelveInsight - PR New","headline":"Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval a","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPRGdKaXRfVFdEcDVnTGdQRFd4NEVRejk5eTNwNXltMFJBZWlmTTlORk1tWWxPd3VmOW9rSDQ3OEE4dGU0M2wtTlF3cmNVS0RnY0o1WmpGNjl0RTltZDJiVmRVOXBjaVcyTDUwYXN2NmxnUDhUVTVsZzZESFB0SXkzX1c4cVVyZXN4ZURDT3FFaE1JV2sxcjc3S01fTll0Z1JSay0xZnBNd1l4ZTlwX2JUVGhTR1MydXl4UjNreklqYTB2bG9BZlZKQWRpbUlKamZ3REltc3ZFS3JpN01zTlFOT2NxNFFYdk01WTFBVGZ1UjltZWRPYktCOGdtVU9OZENMRERCXzZwOGNHaHI2U1ZQV1pwYkx4Q1hEWDFrZGQwZDdrT3FiUXpNckdhWm1PMnUzdWpsV3ktZzNUeWNC?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire UK","summary":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight - PR Newswire UK","headline":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQV19SSmJGenRyTUxPR0twOHlwei1YNTVYUWNYVi1NaGoxU3NpYUdLQjNpamFnR3lKN3JXelRkeHdFWWdDeGRHUkg4YmNkcHFjLWhUNDJlVW5fX0xtQW1VUnVVdHA0d1l2X3RhTDNmUHJqUl9UUTJqZEpBVzdhLTI5SEVsS3lsODNxUG04OWdfUDE4T0hvMk9xUkVqaVNPd0dSOTMxb3U4YTZXTEttQ280SXRvek1uekJfVmZLYTFJWERNYkhoX0hyaWxHMm1Zcl9jcW1fekFyZ3I3MzNWbjlFVThCZG5aMHNDV1I3czZyZ19QZGR2cmlaNXJFSE9KVV9TejdEYXZaUEN3S1ZMNkNnR0JLSnFabXJMY3RIZmttTWx1MXVmZ0hLS0MwdE9aU2lxR2ZwajlqMG9mRzhFSEgwUw?oc=5","date":"2025-12-09","type":"pipeline","source":"PR Newswire","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPd3QyQ0JRbGF1TWJBNGZBTXJRWnV1a1hHVGgwcG5DUUFfMmZGYmlYQnpab3ZBVDhkQlU4cVpOdzZpcHd6NWFPbHhJMkkwcGtDbmQ3c0xUSk1kX055NXN1QzNvbzI3Um1BQ3U2WVlWWWtWUzRZWlBob09CdENuZm4zcGRQdThqbFRZNFNBeXBldVpNZTdWMl9tMmRiMHpHMFA4NnZWblRQTVJVMXhScjRjUXVuUmdBYjFBcDA3djNOaXJ5emNId29xN21VRE16SVk0RDhWcFNfR2NQV3pDUy1fLXBWLWZMRFYyOHYxYzJpa1VEWUtlRVpPNUdSRUxraUZESzhPWEZPdHVCNFRLVTdSbG9icUJaQWhyS050WjNzckRFaWpIYWF3cjVUWjQ4dkZUYTlCRlBadjNadHl4OXJtLXQ5dDJnVmc2?oc=5","date":"2025-07-08","type":"pipeline","source":"GlobeNewswire","summary":"Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire","headline":"Alzheimer’s Therapeutics Market on Upward Trajectory Across","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFA1UTdPZ1ViamVqVzVzUWFMLVg2MU5lal9JLWdDWFF0X2t2SkZXMXVQbVhIWm81OHo0bXBucUVvaVhfT3doRDloWTBBaGdWQ29XTWQ4b05IMXhXWHc4WEVIcFk2aC0yRUNXVnVadTVySUlxZnRSRkln?oc=5","date":"2025-07-07","type":"regulatory","source":"Clinical Trials Arena","summary":"FDA and EMA authorise AB Science’s Phase III trial of prostate cancer treatment - Clinical Trials Arena","headline":"FDA and EMA authorise AB Science’s Phase III trial of prostate cancer treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1pQ1NXdnBEMkNMS2hlbWh3Z2MteGdtQkh6bWdzMkZST2RuN1pwOFJxeW10UzZrTjVBem9JNFNpMy1oNUNHMnE4UFJydlo4NGU5dFdXNjV4d21hNnBNWkg5OEdlSnZaWFVQZ0E?oc=5","date":"2024-03-12","type":"deal","source":"Wiley Online Library","summary":"European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD) - Wiley Onli","headline":"European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSUN0Nm55TDE1LTBBVXFBemhzdTBtaDNub1hrbUpYTDBqR3RFTDdFaFJ4WnBEMjd6UzYtbGgwV0lpM01nOEcwY3BkWnFIR2c3aTA1RnlsbjY1M2lkemd1VEVTSVNGSVp3S1V4dGtBX1lMR2U5azZFR09SOEJ2VE1CNVpMUjZvTGhvdHZBVkRxNmd5ZHZQZ1h3a3A3WkdnR0RlQnMzaHVNWDZCNjJJS2RGMmRqeUZBdGpGMFpsQV9YZXAydUU?oc=5","date":"2021-09-13","type":"trial","source":"drugdiscoverytrends.com","summary":"AB Science points to positive prostate cancer study results for masitinib plus docetaxel - drugdiscoverytrends.com","headline":"AB Science points to positive prostate cancer study results for masitinib plus docetaxel","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQX2ZiUHlRamV5TjJtbl9KNGFoSjc0aDJkd2Vjczl3eFVPN1k5LWNYMlYxUE11SlVIMTVlSkVxaUZJUXNEOU45bV8zR015Y2ZNc0RiSWNJMXU3cVA0T0drS2JEQ0pGU0FGSGgyTm8tQktER2tyNFhnMFhMRk1feHJsVjNMcUh0eE5IYVl6NUtob2dPcFhDV25UaXhTdldRQXR4WmF3?oc=5","date":"2021-06-02","type":"trial","source":"Fierce Biotech","summary":"AB halts masitinib trials after discovering heart disease worry - Fierce Biotech","headline":"AB halts masitinib trials after discovering heart disease worry","sentiment":"negative"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":2,"phase_2":1,"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}